Wall Street analysts expect Intrexon Corporation (NYSE:XON) to report ($0.22) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Intrexon Corporation’s earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.30). Intrexon Corporation posted earnings per share of ($0.24) in the same quarter last year, which indicates a positive year-over-year growth rate of 8.3%. The business is expected to report its next quarterly earnings report on Wednesday, November 8th.

On average, analysts expect that Intrexon Corporation will report full year earnings of ($0.84) per share for the current financial year, with EPS estimates ranging from ($0.96) to ($0.55). For the next financial year, analysts forecast that the business will report earnings of ($0.63) per share, with EPS estimates ranging from ($0.75) to ($0.57). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Intrexon Corporation.

Intrexon Corporation (NYSE:XON) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. The firm had revenue of $54.40 million for the quarter, compared to analysts’ expectations of $57.17 million. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.42) earnings per share.

A number of analysts have recently weighed in on the company. Northland Securities set a $30.00 target price on Intrexon Corporation and gave the company a “buy” rating in a research note on Monday, August 7th. BidaskClub cut Intrexon Corporation from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Finally, Zacks Investment Research downgraded shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Intrexon Corporation presently has a consensus rating of “Hold” and an average price target of $37.60.

WARNING: This report was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/10/04/brokerages-anticipate-intrexon-corporation-xon-will-post-earnings-of-0-22-per-share.html.

Shares of Intrexon Corporation (NYSE XON) opened at 19.47 on Wednesday. The firm has a 50-day moving average price of $18.94 and a 200-day moving average price of $21.12. The firm’s market capitalization is $2.35 billion. Intrexon Corporation has a 52-week low of $17.03 and a 52-week high of $32.90.

In other news, Director Dean J. Mitchell acquired 5,000 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were purchased at an average cost of $18.33 per share, for a total transaction of $91,650.00. Following the transaction, the director now owns 18,103 shares of the company’s stock, valued at $331,827.99. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Randal J. Kirk bought 132,625 shares of the stock in a transaction dated Friday, August 11th. The stock was purchased at an average cost of $18.85 per share, with a total value of $2,499,981.25. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 144,569 shares of company stock worth $2,719,429. Company insiders own 56.30% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in XON. Tower Research Capital LLC TRC lifted its stake in shares of Intrexon Corporation by 2,031.7% during the second quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock valued at $125,000 after acquiring an additional 4,937 shares during the period. Federated Investors Inc. PA bought a new position in Intrexon Corporation in the second quarter valued at about $172,000. Pacer Advisors Inc. boosted its holdings in Intrexon Corporation by 21.6% in the first quarter. Pacer Advisors Inc. now owns 7,352 shares of the biotechnology company’s stock valued at $146,000 after acquiring an additional 1,305 shares during the last quarter. SG Americas Securities LLC bought a new position in Intrexon Corporation in the first quarter valued at about $164,000. Finally, Cullinan Associates Inc. bought a new position in Intrexon Corporation in the second quarter valued at about $201,000. Institutional investors own 82.11% of the company’s stock.

About Intrexon Corporation

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Get a free copy of the Zacks research report on Intrexon Corporation (XON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.